Stock 600513 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Equities

600513

CNE000001DP6

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
9.41 CNY -0.74% Intraday chart for Jiangsu Lianhuan Pharmaceutical Co., Ltd. -2.89% -15.53%
04-29 Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-09 Lianhuan Pharma Obtains China Registration Approval for Antihistamine MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lianhuan Pharma Obtains China Registration Approval for Antihistamine
MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lianhuan Pharma's Production Lines Pass GMP Inspection
MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Jiangsu Lianhuan Pharma Passes GMP Compliance Inspection
MT
MFM KOREA Co., Ltd. announced that it expects to receive KRW 23.99999924 billion in funding from Jiangsu Lianhuan Pharmaceutical Co., Ltd. and other investors
CI
Jiangsu Lianhuan Pharma Gets Nod to Market Ingredient For Drug Against Addison’s Disease
MT
Jiangsu Lianhuan Pharma Plans Listing Unit on ‘New Third Board’
MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Foyou Pharma Passes Drug GMP Compliance Inspection
MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Jiangsu Lianhuan Pharma to Raise 450 Million Yuan From Bond Sale
MT
Lianhuan Pharma Gets Nod for Erectile Dysfunction Drug
MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Jiangsu Lianhuan Pharmaceutical Gets Nod to Market Antihistamine Ingredient in China
MT
Lianhuan Pharma Gets Nod for Anti-Allergy Drug Registration
MT
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600513 Stock
  4. News Jiangsu Lianhuan Pharmaceutical Co., Ltd.